Advertisement

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Coagulation Self-Testing: Devices, Markets, Players and Prospects

http://www.reportlinker.com/p0581170/Coagulation-Self-Testing-Devices-Markets-Players-and-Prospects .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The ability of patients to self-monitor is deemed to be a critical tool in reducing the pathological effects of difficult-to-control disease factors. For the millions of patients in the US and worldwide prescribed warfarin for oral anticoagulation therapy (OAT), the ability to monitor coagulation rates and adjust drug dosage to optimize therapeutic outcomes is a critical element of patient care. The availability of self-testing monitors provides patients with an opportunity to self-test and avoid frequent caregiver visits. Compared to blood glucose monitoring, OAT self-testing presents a higher level of complexity and risk, placing a premium on patient education. A number of companies are now providing services to patients wishing to self-test, acting as a first-line patient resource and assisting with device selection and patient training. Wirelessly-enabled devices that allow patients to share readings with physicians electronically provide an additional safety and compliance benefit. While still a small percentage of all patients, as demographics and awareness drive increases in the diagnosed incidence of underlying conditions, patient self-testing for OAT will increasingly migrate from caregiver facilities and into homes..

Highlights

• Analyzes marketed patient self-testing devices for measuring and monitoring an

'/>"/>

SOURCE

Advertisement
Advertisement